SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Item 9 Labs Corp. – ‘1-A’ on 2/2/22 – ‘EX1A-12 OPN CNSL’

On:  Wednesday, 2/2/22, at 2:47pm ET   ·   Accession #:  1554795-22-45   ·   File #:  24-11795

Previous ‘1-A’:  None   ·   Next & Latest:  ‘1-A/A’ on 2/23/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/02/22  Item 9 Labs Corp.                 1-A                    7:2.1M                                   Sharello Corp./FA

Offering Statement   —   Form 1-A   —   Regulation A/A+

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 1-A         Offering Statement -- primary_doc.xml               HTML      4K 
 2: PART II AND III  Form 1-A Part Ii & Iii                         HTML    812K 
 3: EX1A-3 HLDRS RTS  Exhibit 3.1                                   HTML     67K 
 4: EX1A-4 SUBS AGMT  Exhibit 4.1                                   HTML     41K 
 5: EX1A-11 CONSENT  Exhibit 11.2                                   HTML      5K 
 6: EX1A-11 CONSENT  Exhibit 11.3                                   HTML      6K 
 7: EX1A-12 OPN CNSL  Exhibit 12.1                                  HTML     12K 


‘EX1A-12 OPN CNSL’   —   Exhibit 12.1


This is an HTML Document rendered as filed.  [ Alternative Formats ]



Exhibit 12.1

 

 

 

February 1, 2022

 

Item 9 Labs Corp.

2727 N 3rd Street, Suite 201

Phoenix, AZ 85004

Attn: Board of Directors

 

Re: Regulation A—Tier 2 Offering

      

Ladies and Gentlemen:

 

We have acted, at your request, as special counsel to Item 9 Labs Corp., a Delaware corporation (the “Company”), for the purpose of rendering an opinion as to the legality of units (the “Units”), each Unit comprised of (i) one share (a “Common Share”) of common Stock, par value $0.0001 per share (the “Common Stock”), of the Company and (ii) one warrant (the “Warrant”) exercisable for one share of Common Stock (a “Warrant Share,” and together with the Units, Common Shares and Warrants, the “Securities”) (the “Offering”), to be offered and distributed by the Company pursuant to an offering statement on Form 1-A (the “Offering Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”) under to Regulation A of the Securities Act of 1933, as amended (the “Securities Act”), for the purpose of offering and selling the Securities (the “Offering”).

 

For the purpose of rendering this opinion herein, we have reviewed statutes of the State of Delaware, to the extent we have deemed relevant to the matter opined upon herein, certified or purported true copies of the Articles of Incorporation of the Company and all amendments thereto, the bylaw of the Company, selected proceedings of the board of directors of the Company authorizing the issuance of the Securities, certificates of officers of the Company and of public officials, and such other documents of the Company and of public officials as we have deemed necessary and relevant to the matter opined upon herein. We have assumed, with respect to persons other than directors and officers of the Company, the due and proper election or appointment of all persons signing and purporting to sign the documents in their respective capacities, as stated therein, the genuineness of all signatures, the conformity to authentic original documents of the copies of all such documents submitted to me as certified, conformed and photocopied, including the quoted, extracted, excerpted and reprocessed text of such documents.

 

Based upon the review described above, it is our opinion that

 

(i)the Common Shares are duly authorized and when, as and if issued and delivered by the Company against payment therefore, as described in the Offering Statement, will be validly issued, fully paid and non-assessable shares of Common Stock of the Company;

 

(ii)the Warrants are duly authorized and when, as and if issued and delivered by the Company against payment therefore, as described in the Offering Statement, will constitute valid and legally binding obligations of the Company to issue and sell, upon exercise thereof and payment of the exercise price therefor, the number and type of securities of the Company called for thereby in accordance with the terms thereof and the Warrants are enforceable against the Company in accordance with their terms; provided, however, that the enforceability thereof may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws relating to or affecting creditors’ rights generally and by general principles of equity (regardless of whether such enforceability is considered a proceeding in equity or at law); and

 

(iii)the Warrant Shares are duly authorized and when, as and if issued and delivered by the Company against payment therefore pursuant to the Warrant, as described in the Warrant, will be validly issued, fully paid and non-assessable shares of Common Stock of the Company.

 

We have not been engaged to examine, nor have we examined, the Offering Statement for the purpose of determining the accuracy or completeness of the information included therein or the compliance and conformity thereof with the rules and regulations of the SEC or the requirements of Form 1-A and Regulation A, and we express no opinion with respect thereto. Our forgoing opinion is strictly limited to matters of Delaware corporation law, and we do not express an opinion on the federal law of the United States of America or the law of any state or jurisdiction therein other than Delaware, as specified herein.

 

We hereby consent to the filing of this opinion as Exhibit 12.1 to the Offering Statement and to the reference of our firm under the caption “Legal Matters” in the Offering Circular constituting a part of the Offering Statement. We assume no obligation to update or supplement any of the opinion set forth herein to reflect any changes of law or fact that may occur following the date hereof.

 

 

/s/ Carmel, Milazzo & Feil, LLP

Carmel, Milazzo & Feil, LLP

 

Manhattan Office: 55 West 39th Street, 18th Floor, New York, NY 10018

New York City | New Jersey | Long Island | Beverly Hills | Florida

Website: www.cmfllp.com

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘1-A’ Filing    Date    Other Filings
Filed on:2/2/228-K
2/1/228-K
 List all Filings 
Top
Filing Submission 0001554795-22-000045   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 7, 12:56:07.0pm ET